Volume 29, Number 12—December 2023
CME ACTIVITY - Synopsis
Invasive Nocardia Infections across Distinct Geographic Regions, United States
Table 1
Patient demographics and coexisting conditions by site of diagnosis and transplant status in study of invasive Nocardia infections across 3 distinct geographic regions, United States*
| Category |
Site of diagnosis |
Transplant recipient |
Total, n = 268 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MN, n = 129 | AZ, n = 87 |
FL, n = 52 | No, n = 186 | Yes, n = 82 | |||||
| Demographics | |||||||||
| Age, mean (SD) | 63.4 (16.3) | 65.9 (15.0) | 61.2 (11.7) | 66.1 (15.7) | 58.6 (12.4) | 63.8 (15.1) | |||
| Sex | |||||||||
| M | 61 (47.3) | 41 (47.1) | 37 (71.2) | 83 (44.6) | 56 (68.3) | 139 (51.9) | |||
| F | 68 (52.7) | 46 (52.9) | 15 (28.8) | 103 (55.4) | 26 (31.7) | 129 (48.1) | |||
| White | 121 (97.6) | 71 (84.5) | 39 (76.5) | 173 (96.6) | 58 (72.5) | 231 (89.2) | |||
| Hispanic |
0 (0.0) |
12 (14.0) |
3 (5.9) |
4 (2.2) |
11 (13.4) |
15 (5.7) |
|||
| Coexisting conditions | |||||||||
| Diabetes | 7 (5.4) | 18 (20.7) | 23 (44.2) | 12 (6.5) | 36 (43.9) | 48 (17.9) | |||
| Liver failure | 4 (3.1) | 1 (1.1) | 2 (3.8) | 1 (0.5) | 6 (7.3) | 7 (2.6) | |||
| Renal failure/dialysis | 6 (4.7) | 4 (4.6) | 17 (32.7) | 2 (1.1) | 25 (30.5) | 27 (10.1) | |||
| Active malignancy | 16 (12.5) | 12 (13.8) | 13 (25.0) | 26 (14.0) | 15 (18.5) | 41 (15.4) | |||
| Rheumatologic conditions | 21 (16.4) | 5 (5.7) | 7 (13.5) | 28 (15.1) | 5 (6.2) | 33 (12.4) | |||
| Chronic lung disease | 95 (74.8) | 34 (39.1) | 27 (51.9) | 130 (69.9) | 26 (32.5) | 156 (58.6) | |||
| Transplant recipient |
14 (10.9) |
35 (40.2) |
33 (63.5) |
NA |
NA |
82 (30.6) |
|||
| Transplanted organs | |||||||||
| Kidney | 2 (14.3) | 18 (51.4) | 13 (39.4) | NA | 33 (40.2) | 33 (40.2) | |||
| Liver | 2 (14.3) | 2 (5.7) | 1 (3.0) | NA | 5 (6.1) | 5 (6.1) | |||
| Pancreas | 1 (7.1) | 0 | 0 | NA | 1 (1.2) | 1 (1.2) | |||
| Lung | 1 (7.1) | 0† | 12 (36.4) | NA | 13 (15.9) | 13 (15.9) | |||
| Heart | 2 (14.3) | 9 (25.7) | 2 (6.1) | NA | 13 (15.9) | 13 (15.9) | |||
| Kidney and liver | 1 (7.1) | 0 | 1 (3.0) | NA | 2 (2.4) | 2 (2.4) | |||
| Kidney and pancreas | 0 | 0 | 3 (9.1) | NA | 3 (3.7) | 3 (3.7) | |||
| HSCT |
5 (35.7) | 6 (17.1) |
1 (3.0) | NA | 12 (14.6) | 12 (14.6) | |||
*Values are no. (%) patients except at indicated. AZ, Mayo Clinic Arizona, Phoenix/Scottsdale, Arizona, USA; FL, Mayo Clinic Florida, Jacksonville, Florida, USA; HSCT, hematopoietic stem cell transplant; MN, Mayo Clinic Rochester, Rochester, Minnesota, USA; NA, not applicable. †Lung transplantations not performed at Mayo Clinic Arizona during study period.
1Current affiliation: Simran Gupta, Massachusetts General Hospital & Brigham and Women’s Hospital, Boston, Massachusetts, USA.
2Current affiliation: Kathryn E. Kimes, Honor Health, Phoenix, Arizona, USA.
3Current affiliation: Ahmed Hamdi, Baylor College of Medicine, Houston, Texas, USA.
4Current affiliation: Juan Gea-Banacloche, National Institute for Allergy and Infectious Diseases, Bethesda, Maryland, USA.
5Current affiliation: Prakhar Vijayvargiya, University of Mississippi Medical Center, Jackson, Mississippi, USA.